Nur Indah Fitri

Nur Indah Fitri

Auto-generated profile, based on publicly available information

Nur Indah Fitri

Australian Institute for Bioengineering and Nanotechnology The University of Queensland Brisbane Queensland Australia

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2025 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
RGRaluca Ghebosu
Raluca Ghebosu
Jenifer Pendiuk GonçalvesJenifer Pendiuk Gonçalves
Jenifer Pendiuk Gonçalves
NFNur Indah Fitri
Nur Indah Fitri
DIDalila Iannotta
Dalila Iannotta
MSMohammad Farouq Sharifpour
Mohammad Farouq Sharifpour
JWJoy Wolfram
Joy Wolfram
Extracellular vesicles (EVs) are biological nanoparticles that play important roles in (patho)physiological processes and are promising new therapeutic and diagnostic tools. Recent evidence suggests that other circulating biological nanoparticles, primarily lipoproteins, bind to EVs, changing their biological identity. Such binding has been demonstrated with complex qualitative techniques, such as cryogenic transmission electron microscopy. There is a need to rapidly and simply quantify EV‐lipoprotein binding, as such complexes could have major implications for EV biology and medical applications. This study developed lipoprotein association fluorometry (LAF; based on fluorescent lipophilic indocarbocyanine dyes), as a first‐of‐its‐kind, simple and quick assay to assess EV binding to lipoproteins. The LAF assay was validated with synthetic nanoparticles, small molecules, polymers and proteins that display known interactions with lipoproteins. The LAF assay demonstrates that EVs from various human and non‐human (nematode and bacteria) sources bind to very‐low‐density lipoprotein (VLDL) and low‐density lipoprotein (LDL). Notably, EVs derived from cancerous cells displayed substantially increased binding to VLDL, LDL and plasma compared to EVs from normal cells. Additionally, the LAF assay revealed that EVs from metastatic cancer cells bound to VLDL to a greater extent than those from corresponding patient‐matched non‐metastatic cancer cells. On the contrary, EVs displayed minimal binding to high‐density lipoprotein (HDL). Taken together, the LAF assay is capable of measuring EV‐lipoprotein binding in a simple, rapid and semi‐quantitative manner, leading to new opportunities to probe EV biology and develop novel therapeutics, and diagnostics.